{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:55:51Z","timestamp":1790618151656,"version":"4.1.0"},"reference-count":39,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK","award":["Study number 213172"],"award-info":[{"award-number":["Study number 213172"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,5,26]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify predictors of treatment response to help target mepolizumab to patients with severe asthma with type 2 inflammation (SA-T2) who are most likely to respond to therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting<\/jats:title>\n                    <jats:p>The REal-worlD Effectiveness and Safety of mepolizumab (REDES), a multicentre, observational cohort study, investigated the effectiveness and safety of mepolizumab in Spanish patients with SA-T2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>We conducted a post hoc analysis of data from REDES to examine relationships between patient characteristics and response to mepolizumab to identify predictive markers of response. Outcomes included annualised clinically significant exacerbations (primary), lung function (forced expiratory volume in 1\u2009s), maintenance oral corticosteroid (OCS) dose and Asthma Control Test (ACT) score. Outcomes after 12 months\u2019 treatment with mepolizumab were assessed and stratified by demographic and clinical characteristics. Analyses were descriptive; changes from baseline were summarised as mean (SD) and prespecified two-tailed unpaired t-tests were applied for comparisons (p&lt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>These were stratified by various demographic and clinical characteristics collected during the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 318 patients with SA-T2 were included in the analysis. Mepolizumab was effective in patients with a diverse range of demographic and clinical characteristics. Baseline blood eosinophil count \u2265150\u2009or \u2265300\u2009cells\/\u00b5L or fraction of exhaled nitric oxide (FeNO) \u226525\u2009or \u226550\u2009ppb resulted in a 77%\u201388%\u2009reduction in exacerbations compared with 51%\u201355% in patients with lower baseline levels of these biomarkers (descriptive). Baseline factors of sex, body mass index, smoking status, atopic sensitisation and forced expiratory volume in 1\u2009s had no appreciable effects on exacerbations, maintenance OCS use, lung function or asthma symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This post hoc analysis indicates mepolizumab is likely to provide clinical benefit in patients with SA-T2 across a broad range of patient characteristics. Patients with baseline blood eosinophils of \u2265150\u2009cells\/\u00b5L and\/or FeNO \u226525\u2009ppb are likely to derive more benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>213172.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-105671","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:00:22Z","timestamp":1790614822000},"page":"e105671","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of response to mepolizumab for severe asthma: a REDES study post hoc analysis"],"prefix":"10.1136","volume":"16","author":[{"given":"Marina","family":"Blanco-Aparicio","sequence":"first","affiliation":[{"name":"Hospital Universitario A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Carrillo-Diaz","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn, Las Palmas de Gran Canaria, Spain"},{"name":"Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Martinez-Moragon","sequence":"additional","affiliation":[{"name":"Hospital Universitario Doctor Peset, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ba\u00f1as-Conejero","sequence":"additional","affiliation":[{"name":"Specialty Care Medical Department, GSK, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-Guadalupe","family":"S\u00e1nchez-Herrero","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Luz Quironsalud, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-773X","authenticated-orcid":false,"given":"Christian","family":"Domingo-Ribas","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Parc Taul\u00ed Hospital Universitari, Sabadell, Spain"},{"name":"Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Spain"},{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2026092810001426000_16.9.e105671.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2026092810001426000_16.9.e105671.2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jaip.2019.11.024","article-title":"Eosinophilic asthma","volume":"8","author":"Nelson","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026092810001426000_16.9.e105671.3","doi-asserted-by":"crossref","unstructured":"Bagnasco D , Testino E , Nicola S , et al . Specific therapy for T2 asthma. J Pers Med 2022;12. doi:10.3390\/jpm12040593","DOI":"10.3390\/jpm12040593"},{"key":"2026092810001426000_16.9.e105671.4","doi-asserted-by":"crossref","unstructured":"Pelaia C , Paoletti G , Puggioni F , et al . Interleukin-5 in the pathophysiology of severe asthma. Front Physiol 2019;10. doi:10.3389\/fphys.2019.01514","DOI":"10.3389\/fphys.2019.01514"},{"key":"2026092810001426000_16.9.e105671.5","doi-asserted-by":"publisher","DOI":"10.1111\/all.14297"},{"key":"2026092810001426000_16.9.e105671.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.043"},{"key":"2026092810001426000_16.9.e105671.7","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/all.15627","article-title":"IL-5 receptor expression in lung fibroblasts: Potential role in airway remodeling in asthma","volume":"78","author":"Bajbouj","year":"2023","journal-title":"Allergy"},{"key":"2026092810001426000_16.9.e105671.8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s40265-017-0810-5","article-title":"Overlapping effects of new monoclonal antibodies for severe asthma","volume":"77","author":"Domingo","year":"2017","journal-title":"Drugs"},{"key":"2026092810001426000_16.9.e105671.9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/14712598.2019.1610382","article-title":"An evaluation of mepolizumab for the treatment of severe asthma","volume":"19","author":"Morjaria","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2026092810001426000_16.9.e105671.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2026092810001426000_16.9.e105671.11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026092810001426000_16.9.e105671.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2026092810001426000_16.9.e105671.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2026092810001426000_16.9.e105671.14","doi-asserted-by":"crossref","unstructured":"Crimi C , Campisi R , Cacopardo G , et al . Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities. World Allergy Organ J 2020;13. doi:10.1016\/j.waojou.2020.100462","DOI":"10.1101\/2020.05.26.20112052"},{"key":"2026092810001426000_16.9.e105671.15","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"2026092810001426000_16.9.e105671.16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/02770903.2021.1897835","article-title":"Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study","volume":"59","author":"Enr\u00edquez-Rodr\u00edguez","year":"2022","journal-title":"J Asthma"},{"key":"2026092810001426000_16.9.e105671.17","doi-asserted-by":"crossref","unstructured":"Harrison T , Canonica GW , Chupp G , et al . Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J 2020;56. doi:10.1183\/13993003.00151-2020","DOI":"10.1183\/13993003.00151-2020"},{"key":"2026092810001426000_16.9.e105671.18","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/j.clinthera.2021.03.023","article-title":"Real-world effectiveness of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis","volume":"43","author":"Li","year":"2021","journal-title":"Clin Ther"},{"key":"2026092810001426000_16.9.e105671.19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000511147","article-title":"Mepolizumab effectiveness and allergic status in real life","volume":"182","author":"Sposato","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"2026092810001426000_16.9.e105671.20","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02098-1"},{"key":"2026092810001426000_16.9.e105671.21","first-page":"1090","article-title":"The relationship of asthma biologics to remission for asthma","volume":"9","author":"Menzies-Gow","year":"2021","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"2026092810001426000_16.9.e105671.22","doi-asserted-by":"crossref","unstructured":"Pavord I , Gardiner F , Heaney LG , et al . Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. Front Immunol 2023;14. doi:10.3389\/fimmu.2023.1150162","DOI":"10.3389\/fimmu.2023.1150162"},{"key":"2026092810001426000_16.9.e105671.23","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma-A real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026092810001426000_16.9.e105671.24","doi-asserted-by":"crossref","first-page":"32139455","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"key":"2026092810001426000_16.9.e105671.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105806"},{"key":"2026092810001426000_16.9.e105671.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.10.005"},{"key":"2026092810001426000_16.9.e105671.27","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","article-title":"Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy","volume":"145","author":"Howarth","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2026092810001426000_16.9.e105671.28","doi-asserted-by":"crossref","first-page":"476","DOI":"10.18176\/jiaci.0905","article-title":"REDES Study: mepolizumab is effective in patients with severe asthma and comorbid nasal polyps","volume":"33","author":"Arismendi","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2026092810001426000_16.9.e105671.29","doi-asserted-by":"crossref","first-page":"106595","DOI":"10.1016\/j.rmed.2021.106595","article-title":"Efficacy of mepolizumab in usual clinical practice and characteristics of responders","volume":"187","author":"Rodr\u00edguez-Garc\u00eda","year":"2021","journal-title":"Respir Med"},{"key":"2026092810001426000_16.9.e105671.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.008"},{"key":"2026092810001426000_16.9.e105671.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.01.011"},{"key":"2026092810001426000_16.9.e105671.32","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2020-BTSabstracts.248"},{"key":"2026092810001426000_16.9.e105671.33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13223-020-00507-0","article-title":"Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts","volume":"17","author":"Ghassemian","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2026092810001426000_16.9.e105671.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202003-0729LE"},{"key":"2026092810001426000_16.9.e105671.35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-13-11"},{"key":"2026092810001426000_16.9.e105671.36","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205634"},{"key":"2026092810001426000_16.9.e105671.37","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/cea.13882","article-title":"Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes","volume":"51","author":"Fong","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"2026092810001426000_16.9.e105671.38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12931-021-01746-4","article-title":"Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions","volume":"22","author":"Gibson","year":"2021","journal-title":"Respir Res"},{"key":"2026092810001426000_16.9.e105671.39","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.9120-11ST"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-105671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:00:27Z","timestamp":1790614827000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-105671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,28]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2025-105671"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-105671","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}